Clinical Trials in Cardiovascular Disease
Cardiovascular Research
At Saint Alphonsus, we are committed to improving heart health and helping people live longer, healthier lives. One way we do this is by conducting cardiovascular research and sharing what we learn with the medical community.
Heart and blood vessel diseases are among the leading causes of death and disability in the United States and around the world. Our research focuses on finding better ways to prevent, diagnose, and treat these conditions.
Our team studies how different treatments, medications, and medical devices affect patient health and recovery. These research projects are supported by grants, charitable donations, government agencies, foundations, and industry partners.
As we learn more about heart disease, we use that knowledge to improve patient care and develop new treatment options. Our goal is to give patients access to clinical research and clinical trial opportunities that may help advance heart care for future generations.
By working closely with experienced cardiologists and research specialists, we support local, national, and international studies focused on improving cardiovascular health.
Our Vision
We strive to:
- Develop and participate in innovative clinical research studies.
- Improve heart care through new discoveries and treatments.
- Educate healthcare professionals and community members about heart disease prevention, treatment, and early warning signs.
- Help people make informed choices to improve their heart health.
Areas of Research
Our research focuses on:
- Cardiac intensive care
- Cholesterol and lipid disorders
- Heart Failure
- Heart imaging and diagnostic testing
- Heart rhythm disorders (electrophysiology)
- High blood pressure (hypertension)
- Interventional cardiology procedures
- Preventive heart care
- Women's heart health
Current Cardiovascular Research Studies
COMPLETE TAVR Clinical Trial
Sponsor: University of British Columbia and Edwards Lifesciences
Primary Investigator: Joseph Walsh, MD - Interventional Cardiology
The purpose of the study is to find patients with Coronary Artery Disease (CAD) who had successful Transcatheter Aortic Valve Replacement (TAVR) with a balloon expandable heart valve, whether restoring blood flow to all blocked or narrowed arteries via percutaneous coronary intervention (PCI) using coronary stent(metal scaffold) is better than treat the coronary artery disease with medications only following TAVR.
Currently Enrolling subjects at Saint Alphonsus Regional Medical Center. Please contact the research coordinators, Erika Calhoun at 208-302-9217 or Kristina Slanda at 208-302-0066 to discuss your participation in the clinical trial.
PROGRESS CAP
Sponsor: Edwards Lifesciences
Primary Investigator: Joseph Walsh, MD - Interventional Cardiology
This Continued Access Protocol (CAP) trial is being done to see if the SAPIEN 3™ and SAPIEN 3 Ultra™ Transcatheter Heart Valve is beneficial for patients with moderate, calcific aortic stenosis. Aortic Stenosis is a progressive disease, which means it will get worse over time. Because of this, doctors will typically measure it as Mild, Moderate, or Severe Aortic Stenosis. The stage of aortic stenosis depends on how damaged your aortic valve is. Normally, only patients that have Severe Aortic Stenosis with symptoms can have their valve replaced. This Continued Access Protocol (CAP) trial will help us see if replacing the valve earlier can lead to health improvements by stopping or preventing the worsening of damage to the heart for patients with this condition.
Currently Enrolling subjects at Saint Alphonsus Regional Medical Center. Please contact the research coordinators, Erika Calhoun at 208-302-9217 or Kristina Slanda at 208-302-0066 to discuss your participation in the clinical trial.